Summit Therapeutics holders back all 2026 proposals
Summit Therapeutics Inc. reported results of its 2026 Annual Meeting of Stockholders held on June 10, 2026.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Summit Therapeutics Inc. reported results of its 2026 Annual Meeting of Stockholders held on June 10, 2026. Stockholders elected nine directors to serve until the 2027 annual meeting and ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Stockholders approved, on a non-binding advisory basis, the compensation of the company’s named executive officers. They also approved an amendment to the Summit Therapeutics Inc. 2020 Stock Incentive Plan to increase the number of shares of common stock issuable under the plan by 8,000,000 shares, providing additional equity for future grants.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Plan share increase: 8,000,000 shares
Auditor ratification votes for: 677,302,337 votes
Say-on-pay votes for: 622,624,328 votes
+2 more
5 metrics
Plan share increase
8,000,000 shares
Additional shares issuable under 2020 Stock Incentive Plan
Auditor ratification votes for
677,302,337 votes
PricewaterhouseCoopers LLP for fiscal year ending December 31, 2026
Say-on-pay votes for
622,624,328 votes
Non-binding advisory approval of named executive officer compensation
Plan amendment votes for
619,799,393 votes
Approval of 8,000,000-share increase under 2020 Stock Incentive Plan
Highest director support
646,659,701 votes
Votes for director nominee Jeff Huber
Key Terms
non-binding advisory vote, independent registered public accounting firm, broker non-votes, Annual Meeting of Stockholders, +1 more
5 terms
non-binding advisory vote financial
"a non-binding advisory vote to approve the compensation paid to the Company’s named executive officers"
A non-binding advisory vote is a shareholder vote that expresses investors’ opinion on a proposal (such as executive pay, corporate policy, or governance practices) but does not legally force the company to act. Think of it like a customer survey: it signals whether owners approve or disapprove and can pressure boards and managers to change course, so investors watch the result as an indicator of governance risk and potential future shifts in company strategy or leadership.
independent registered public accounting firm financial
"the ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
broker non-votes financial
"as well as the number of abstentions and broker non-votes, as to each such matter"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
Annual Meeting of Stockholders financial
"held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”)"
Stock Incentive Plan financial
"Summit Therapeutics Inc. 2020 Stock Incentive Plan (the “Plan”) to increase the number of shares"
A stock incentive plan is a company program that gives employees or directors pieces of ownership or the right to buy shares over time, similar to receiving a bonus paid in company stock instead of cash. Investors pay attention because these plans align staff incentives with long‑term company performance but can also dilute existing shareholders and affect reported profits when grants are expensed, so they influence both ownership percentages and financial results.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Summit Therapeutics (SMMT) stockholders approve at the 2026 Annual Meeting?
Stockholders approved all four proposals presented. They elected nine directors, ratified PricewaterhouseCoopers LLP as auditor for 2026, supported executive compensation in a non-binding advisory vote, and approved an 8,000,000-share increase to the 2020 Stock Incentive Plan for future equity awards.
How did Summit Therapeutics (SMMT) vote on the 2020 Stock Incentive Plan amendment?
Stockholders approved the stock plan amendment with strong support. The proposal to increase the number of shares issuable under the 2020 Stock Incentive Plan by 8,000,000 shares received 619,799,393 votes for, 27,247,910 against, and 124,199 abstentions, plus 30,576,341 broker non-votes.
Were Summit Therapeutics (SMMT) directors re-elected at the 2026 Annual Meeting?
Nine directors were elected to serve until the 2027 meeting. Each nominee, including Robert W. Duggan and Manmeet Soni, received a majority of votes cast, with individual support ranging from about 622 million to over 646 million votes for, plus 30,576,341 broker non-votes for each.
Did Summit Therapeutics (SMMT) stockholders approve the auditor for 2026?
Yes, stockholders ratified the company’s 2026 auditor. The appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026 received 677,302,337 votes for, 85,284 against, and 360,222 abstentions, with no broker non-votes reported.
How did Summit Therapeutics (SMMT) stockholders vote on executive compensation?
Executive pay received advisory stockholder approval. The non-binding advisory vote on compensation for named executive officers had 622,624,328 votes for, 24,445,791 against, and 101,383 abstentions, along with 30,576,341 broker non-votes, indicating overall support for the company’s compensation practices.
AI-generated analysis. How Rhea-AI works. Not financial advice.
